Royalty Report: Supply, Medical, Drugs – Collection: 6732

License Grant

Foundation, formed by Licensee's President, grants an exclusive, worldwide, with the right to grant sublicenses through multiple tiers of sublicenses, in and to, the Technology, Licensed Products, Licensed Improvements, and Patents; and to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products.

License Property

The Licensor is engaged in research and development of stem cells and expansion laboratory services and interested in developing and commercializing the Technology.

The Licensee licensed from the Licensor the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack.  The Licensor was formed by the Licensee President and its Chief Scientific Officer and Vice-President, to develop cellular technology for patients who have suffered myocardial infarctions.

The technology involves a method of preparing and using stromal cells for the treatment of cardiac diseases.  A preferred embodiment of the technology is:
a) enriching unique cells from bone marrow samples;
b) expanding these cells using a proprietary patent-pending method; and
c) harvesting the stromal cell product for potential therapeutic use

License Grant

The University grants an exclusive, license, including the right to grant sublicenses, under the Patent Rights, to make, have made, sell, offer for sale, have sold, use, import, and have imported Licensed Products in the Field.

License Property

The patents are for Non-Human Mammal Having a Graft and Methods of Delivering Protein to Myocardial Tissue; and. Myocardial Grafts and Cellular Composition.

Field of Use

Licensee develops and manufacture fully functioning human cells in industrial quantities to precise specifications. Licensee's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics.

License Grant

The Company Licensed from a certain Foundation, a related party, the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack.

License Property

The Company has sub-Licensed the StromaCel Technology to the sublicensee, but the Company will remain responsible for all costs associated with patent prosecution for the StromaCel Technology.

In the event of bankruptcy, the rights to the Technology granted by the License revert to the Foundation.

Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.

Field of Use

The rights granted apply to the medical industry relating to stem cell therapeutics.

License Grant

The Licensee, a Belgian company, was granted an exclusive, worldwide License to make, use, modify, enhance, promote, market and/or sell the Cardiogenic Cocktail for the production of Cardiac Cells and Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure. The Licensee was also granted a non-exclusive, worldwide License to Licensed know-how in connection with the Licensed inventions within the same field.

License Property

The Licensor has technology in the field of cardiovascular regeneration or protection, including certain related patents.

LICENSED INVENTIONS means “Cardiogenic Cocktail for the production of Cardiac Cells” (Mayo Reference number MMV#2004-182) and “Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure” (Mayo Reference number MMV#2007-121). If not patented, then the Licensed Inventions are MAYO’s trade secret. To Mayo’s knowledge, the two inventions explicitly listed encompass Mayo’s inventions and intellectual property on guided cardiopoiesis as of the date of execution of the Second Amendment. Licensed Inventions also includes the following patent applications, and all divisionals, continuations and continuations in part based thereon, and any patents which may issue therefrom, and any reissues or extensions thereof (together, the “Licensed Patents”) and know-how.
Licensed Inventions includes those patents listed below:
2007-121, Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure,
2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.
And the related Patents and Patent Applications;
06/592,871 Stem Cells and treatment of Vascular Tissue
06/680,775 Treating Cardiovascular Tissue
06/832,845 Methods and Materials for providing Cardiac Cells
PCT/US2005/026800 Treating Cardiovascular Tissue
PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue
PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue
PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells

Field of Use

FIELD OF USE means cardiovascular regeneration or protection.

The Licensee has developed C-Cure based on technology Licensed from the Licensor. In HF the heart is unable to pump enough blood to meet the body's metabolic needs. In the C-Cure process, stem cells are collected from an ischemic HF patient through bone marrow aspiration during an outpatient procedure. The stem cells are then harvested, selected, expanded and differentiated into cardiopoietic cells at our manufacturing facility, yielding a homogeneous and pure cardiopoietic cell population. The cardiopoietic cells are then re-injected into the heart of the ischemic HF patient with our C-Cathez cell injection catheter.